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Abstract
Background: Clinical effects and outcomes of a single dose etomidate prior to intubation in the intensive care
setting is controversial. The aim of this study is to evaluate the association of a single dose effect of etomidate
prior to intubation on the mortality of septic cirrhotic patients and the impact of the subsequent use of low dose
hydrocortisone.
Methods: This is a nested-cohort study within a randomized double blind placebo controlled study evaluating the
use of low dose hydrocortisone in cirrhotic septic patients. Cirrhotic septic patients ≥ 18 years were included in the
study. Patients who received etomidate prior to intubation were compared to those who did not receive
etomidate for all cause 28-day mortality as a primary outcome.
Results: Sixty two intubated patients out of the 75 patients randomized in the initial trial were eligible for this
study. Twenty three of the 62 intubated patients received etomidate dose prior to intubation. Etomidate use was
not associated with all cause 28-day mortality or hospital mortality but was associated with significantly higher ICU
mortality (91% vs. 64% for etomidate and controls groups, respectively; p = 0.02). Etomidate patients who received
subsequent doses of hydrocortisone required lower doses of vasopressors and had more vasopressor-free days but
no improvement in mortality.
Conclusions: In this group of septic cirrhotic patients with very high mortality, etomidate increased ICU mortality.
Subsequent use of hydrocortisone appears to have no benefit beyond decreasing vasopressor requirements. The
lowest mortality was observed in patients who did not receive etomidate but received hydrocortisone.
Background
Hypoxemia, hypotension, volume depletion are com-
monly present in septic shock patients and induction of
anesthesia may cause cardiovascular collapse. This effect
is thought to be least with etomidate making it the
favored agent to use for rapid-sequence intubation (RSI)
of patients who have or are at risk of hemodynamic col-
lapse increasing its use in the critical care setting [1-4].
However, etomidate use is not without risks as it has
been shown to suppress the adrenal function through the
inhibition of 11 b-hydroxylase enzyme that converts 11
b-deoxycortisol into cortisol in the adrenal gland leading
to a state of relative adrenal insufficiency that may persist
for up to 72 hours [5-10]. What remains controversial
are the clinical effects and outcomes associated with the
use of a single dose intravenous administration of etomi-
date prior to intubation in the intensive care setting with
some studies linking its use to increased mortality
[11-17] while others showing no effect [18-20]. Conse-
quently, some of the intensive care literature calls for a
ban of its use in this population, while others suggest
that its use should be supplemented with steroid replace-
ment to counteract the adrenal suppression effects;
although this has not been studied prospectively and the
recommendations have been based on observational stu-
dies [21-26].
Adrenal insufficiency is a well-documented entity in
cirrhotic patients, with an incidence of up to 72%. It is
described as the “Hepatoadrenal syndrome” and is asso-
ciated with worse clinical outcomes [27-30]. Moreover,
cirrhotic septic patients are a very vulnerable group of
patients with a mortality rate that can reach up to 70%
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tributes to increased mortality in septic cirrhotic patients
(via worsening adrenal suppression or other unclear
mechanisms) is still to be answered. Thus, the objective
of this study was to evaluate the association between a
single dose effect of etomidate given prior to intubation
on the mortality of septic cirrhotic patients, and the
impact of the subsequent use of low dose hydrocortisone
supplementation.
Methods
Setting
This study was conducted at a 900-bed tertiary care aca-
demic medical center accredited by the Joint Commis-
sion International. Cirrhotic patients with septic shock
are admitted to the 21-bed medical-surgical ICU and
managed by a multidisciplinary team including a 24
hour board certified intensivists, respiratory therapists,
clinical pharmacists, physiotherapists and nutritional
therapists.
Design
This was a nested cohort study within a randomized, dou-
ble blind, placebo controlled trial evaluating the use of low
dose hydrocortisone in septic cirrhotic patients. Details of
the original study are published elsewhere [33]. The data
regarding etomidate was already collected for the main
study and required no additional data collection for the
current study. Consecutive cirrhotic patients were
included in the study if they were aged > 18 years and pre-
sented with septic shock in accordance with hypotension
defined as arterial blood pressure less than 90 mmHg and
mean arterial pressure of below 65 mm Hg for at least one
hour despite adequate fluid resuscitation and requiring
vasoactive support. Patients were randomized to receive
either hydrocortisone (Hydrocortisone, Pharmacia &
Upjohn, Belgium) 50 mg in 5 ml syringe or placebo as
5 ml normal saline every 6 hours. Exclusion criteria
included hypovolemic or hemorrhagic shock, known adre-
nal insufficiency, any prior systemic steroids usage and
contraindication to steroid use. Both treatment and pla-
cebo groups were treated according to a standardized pro-
tocol of empiric antibiotic therapy and vasopressor
support. The study was approved by the Institutional
Review Board (IRB) and was registered at the Current
Controlled Trials registry [31]. The trial was conducted
from April 2004 to October 2007. Results showed no
improved 28 day survival with the administration of
hydrocortisone in spite of the initial hemodynamic bene-
fits rather it was associated with increased incidence of
adverse side effects.
All intubated patients were identified from the original
study to be included in the current one.
Exposure to etomidate
Patients who received a single dose of etomidate (Etomi-
date group) prior to intubation were compared to those
that did not receive etomidate (Control group) for out-
comes. Etomidate exposure was defined as those patients
who received 20 mg of etomidate (Etomidate-Lipuro
®,
B-Braun, Germany or Hypnomidate
®, Janssen-cilag, UK)
immediately prior to intubation. Etomidate was adminis-
tered at the discretion of the treating physician.
Outcomes
T h ep r i m a r yo u t c o m eo ft h es t u d yw a sa l lc a u s e2 8 - d a y
mortality. Secondary outcomes considered were ICU
and hospital mortality, ICU and hospital length of Stay
(LOS), vasopressor doses, mechanical ventilation-free
days, vasopressor-free days.
Data collection
Data pertaining to our study was extracted from the origi-
nal study database. Baseline data collection included
demographics, Acute Physiology and Chronic Health Eva-
luation (APACHE) II Score [34], Sequential Organ Failure
Assessment (SOFA) score [35], Child Pugh Score [36],
baseline cortisol, delta cortisol post adenocorticotropin sti-
mulation test (ACTH), and baseline hemodynamic para-
meters. Additional collected data included baseline liver
function tests and daily parameters including complete
blood count, partial pressure of arterial oxygen to the frac-
tion of inspired oxygen Pao2/Fio2 ratio, albumin, lactic
acid, international normalized ratio (INR), vasopressor
requirements, hemodynamic parameters, source of infec-
tion and etiology of cirrhosis.
Statistical analysis
Baseline characteristics for the exposure groups (Etomi-
date and control groups) were summarized by providing
the mean and standard deviation (±) for the continuous
variables, and the number and percent for the categorical
variables. Association between etomidate use and the dif-
ferent characteristics and outcomes was assessed by calcu-
lating the p-values using the Chi-square or Fisher’st e s t
(for categorical variables) and the Student’st - t e s to r
Wilcoxon-Mann-Whitney test (for continuous variables),
as appropriate.
Subgroup analysis was carried out to examine the asso-
ciation of hydrocortisone use to all cause 28-day mortality,
ICU and hospital mortality among the etomidate and con-
trol patients. Multivariate logistic regression analysis was
carried out to assess the association between etomidate use
and mortality when adjusting for different clinically rele-
v a n tf a c t o r sa sw e l la st h o s ef a c t o r st h a ts h o w e ds t a t i s t i c a l l y
significant differences. Variables adjusted for in the regres-
sion model were APACHE, Child Pugh Score, bilirubin,
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(ALT). Odds ratio (OR) and 95% confidence interval (CI)
were calculated. Statistical significance was defined as P
value ≤ 0.05. Data management and analyses were per-
formed by the statistical analysis software (SAS, Release 8,
SAS Institute Inc., Cary, NC, 1999, USA).
Results
Patient population
Of the 75 patients randomized to the original study, 62
intubated patients were identified of whom 23 received
etomidate prior to intubation (Etomidate group) and 39
did not (Control group). Baseline characteristics were
comparable between the patients receiving etomidate and
control. Baseline cortisol, delta cortisol after ACTH test
were lower in the etomidate group than the control group
but none of these parameters reached statistical signifi-
cance. Child Pugh Score, APACHE II score, SOFA score,
hemodynamic parameters, laboratory parameters, duration
of shock or vasopressor doses prior to inclusion, source of
infection and etiology of disease were all comparable
between the two groups. Pulmonary infections were the
most common source of sepsis followed by spontaneous
bacterial peritonitis in both etomidate and control groups
with no statistically significant difference. Furthermore,
hepatitis C was the most common etiology for cirrhosis.
(Table 1)
Mortality
The all cause 28-day mortality in the etomidate group was
91% compared to 85% in the control group (p = 0.45) and
the hospital mortality was 100% compared to 95% in the
control group; (p = 0.27). Etomidate administration was
associated with a statistically higher ICU mortality com-
pared to control (91% vs.64%; p = 0.02) (Table 2). Multi-
variate logistic regression analysis controlling for multiple
baseline variables (APACHE, Child Pugh Score, bilirubin,
AST and ALT) showed that the adjusted odds ratio of
ICU mortality with etomidate was 5.22 (CI 1.04-26.13).
Secondary outcomes
Etomidate group had less ventilator-free days compared to
control group (2.3 ± 4.6 vs.6 ± 7.5; P = 0.02). Furthermore,
etomidate group had higher vasopressor requirements vs.
control, lesser vasopressor-free days, longer length of stay
but these parameters did not reach statistical significance.
(Table 2)
Effects of hydrocortisone vs. placebo in the etomidate
group
Hydrocortisone was used in 14 of the 23 patients (61%)
who received etomidate, while the other 9 received pla-
cebo. There was no difference in all cause 28-day
mortality, ICU mortality or hospital mortality among eto-
midate users whether they received hydrocortisone or
placebo.
However, the use of hydrocortisone vs. placebo in the
etomidate group was associated with more vasopressor-
free days (4.6 ± 6.93 vs. 1.1 ± 3.3; p = 0.05); lower vaso-
pressor requirements measured by delta norepinephrine
(day3-day1) (-0.10 ± 0.26 vs. 0.31 ± 0.36; p = 0.01); and
more ventilation-free days (3.6 ± 5.6 vs.0.2 ± 0.4; p = 0.04).
(Table 3, Figure 1)
Effects of hydrocortisone vs. placebo in the control group
In the control group, administration of hydrocortisone did
not improve all cause 28-day mortality, ICU mortality and
hospital mortality compared to placebo. The lowest rate of
ICU mortality in this study population was in the sub-
group of patients that did not receive etomidate but
received hydrocortisone (60%); however this was statisti-
cally significant only in comparison to the group that
received etomidate and placebo (p = 0.03). (Figure 1)
Patients who received hydrocortisone in this group had
more vasopressor-free days than those who received pla-
cebo but that did not reach statistical significance. More-
over, again the use of hydrocortisone was associated with
lower vasopressor requirements in this population (-0.20 ±
0.33 vs.0.06 ± 0.28; p = 0.02). (Table 3)
Discussion
Our study showed that etomidate was associated with
increased ICU mortality in cirrhotic septic patients. The
administration of hydrocortisone improved hemodynamics
but did not improve survival irrespective of whether the
patient received etomidate or placebo. The lowest mortal-
ity was observed in patients who did not receive etomidate
but received hydrocortisone.
Etomidate has been a favored agent for rapid sequence
intubation due to its presumed hemodynamic profile but
it has been shown to be strongly associated with adrenal
insufficiency even after single doses. This was shown in
several retrospective and prospective studies in the pedia-
tric and adult population particularly in critically ill
patients with sustained adrenal insufficiency that can
extend up to 72 hours [5-19,37]. Our results showed lower
baseline cortisol, lower delta cortisol after ACTH test in
the etomidate group compared to placebo but that did not
reach statistical significance.
The impact of adrenal suppression by etomidate on
mortality in the critically ill septic shock patients is still
not clearly understood and highly debated with conflict-
ing results and conclusions mainly from retrospective
cohorts with many limitations. Malerba et al., in a retro-
spective study involving mechanically ventilated patients
(33.9% had severe sepsis) demonstrated that etomidate
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cularly among non-responders to ACTH test (70.4% of
non-responders vs.31.4% of responders) [12]. Further-
more, Annane et al. reported increased mortality rates
among patients who received etomidate prior to intuba-
tion in a randomized placebo controlled trial looking at
the effects of low-dose corticosteroid administration in
critically ill septic shock patients [38]. More recently,
Cuthberston et al. in a priori sub-study of the CORTI-
CUS study reported higher mortality rate that was only
apparent after 10 days of ICU stay (42.7% vs. 30.5%, p =
0.02) [17].
Not all literature supports the theory of increased
mortality by etomidate in the critically ill septic shock
patients. Mohammad et al. in a retrospective study of
152 septic shock patients, who had received etomidate
did not show increased mortality versus control (63 vs.
55%, p = 0.45) in spite of adrenal suppressive effects
[11]. Similarly, Ray et al. in a review of 159 septic shock
patients found no difference in mortality among patients
Table 1 Baseline characteristics
Etomidate Control P-Value
N = 23 N = 39
Age (years), mean ± SD 64.0 ± 10.0 58.0 ± 13.0 0.10
Sex, female, No. (%) 9 (39) 16 (41) 0.88
APACHE II, mean ± SD 32.6 ± 6.6 30.2 ± 7.6 0.20
Child-Pugh, mean ± SD 10.8 ± 1.8 11.5 ± 1.9 0.16
SOFA, mean ± SD 15.0 ± 2.9 15.3 ± 3.7 0.79
Baseline cortisol (nmol/L), mean ± SD
a 446.6 ± 283.5 671.9 ± 623.4 0.05
Delta cortisol post ACTH, mean ± SD 99.9 ± 186.5 160.2 ± 343.3 0.40
Mean arterial pressure (mmHg), mean ± SD 58.9 ± 9.1 60.0 ± 7.4 0.58
Bilirubin (μmol/L), mean ± SD
a 359.2 ± 337.7 331.9 ± 266.3 0.73
Lactic acid (mmol/L), mean ± SD
a 3.7 ± 2.7 4.9 ± 4.9 0.21
INR, mean ± SD 2.6 ± 1.5 2.7 ± 1.4 0.84
Ammonia (μmol/L), mean ± SD
a 122.2 ± 147.9 110.4 ± 66 0.72
AST (U/L), mean ± SD 93.0 ± 94.0 273.7 ± 627.7 0.08
ALT (U/L), mean ± SD 43.0 ± 33.3 74.1 ± 108.9 0.10
ALK (U/L), mean ± SD 150.6 ± 131.3 132.5 ± 81.6 0.56
Albumin in (G/L), mean ± SD 31.5 ± 7.3 32.2 ± 6.4 0.70
Platelets (10^9 g/L), mean ± SD 87.2 ± 59.2 111.7 ± 84.2 0.22
Hemoglobin (g/L), mean ± SD 81.7 ± 23.3 85.9 ± 15.4 0.45
WBC (10^9/L), mean ± SD 13.6 ± 8 13.1 ± 8.5 0.82
PaO2/FiO2, mean ± SD 225.9 ± 121.1 230.5 ± 144 0.90
Duration of shock before inclusion (Hours), mean ± SD 18.2 ± 15 12.5 ± 16.1 0.17
Norepinephrine dose at inclusion (μcg/kg/min), mean ± SD 0.4 ± 0.4 0.36 ± 0.4 0.54
Dopamine dose at inclusion (μcg/kg/min), mean ± SD 4.1 ± 6.3 3.3 ± 6 0.60
Source of Infection, No. (%)*
Pulmonary 9 (39.1) 15 (38.5) 0.96
UTI 6 (26.1) 6 (15.4) 0.33
Skin 2 (8.7) 1 (2.6) 0.55
SBP 7 (30.4) 13 (33.3) 0.81
No clear source 6 (26.1) 9 (23.1) 0.79
Other abdominal 1 (4.3) 6 (15.4) 0.24
Etiology of liver disease, No. (%)
HEP C 11 (47.8) 21 (53.9) 0.68
HEP B 7 (30.4) 8 (20.5)
Others (Schistomiasis, auto-immune hepatitis, etc) 5 (21.7) 10 (25.6)
SD: Standard Deviation, APACHE: Acute Physiology and Chronic Health Evaluation, SOFA: Sequential Organ Failure Assessment, ACTH: Adenocorticotropin
stimulation test, INR: International Normalized Ratio; PaO2:FiO2 Ratio: the ratio of partial pressure of oxygen to the fraction of inspired oxygen; UTI: Urinary tract
infection, SBP: Spontaneous bacterial peritonitis
a To convert bilirubin to mg/dL divide by 17.1, ammonia to μg/dL divide by 0.587, lactic acid to mg/dL divide by 0.111, cortisol to μg/dL divide by 27.59
* The numbers may add up to more than 100% because some patients had more than one source.
Cherfan et al. BMC Clinical Pharmacology 2011, 11:22
http://www.biomedcentral.com/1472-6904/11/22
Page 4 of 8that used etomidate versus other induction agents [18].
A more recent study by Baird et al. also did not support
the association of increased mortality by etomidate. His
study reviewed the outcomes of 525 consecutive patients
of whom only 9% were septic patients. They underwent
rapid sequence intubation in the emergency department
and were subsequently admitted to the intensive care
unit. After correction for age, APACHE II score and
presenting diagnosis, etomidate was not an independent
predictor of hospital mortality [19]. Jabre et al. con-
ducted the only prospective randomized controlled trial
comparing etomidate to another agent in rapid sequence
intubation. Their study enrolling 655 trauma and septic
patients showed no increased mortality with the use of
etomidate compared to ketamine. Again, etomidate was
associated with a significantly higher adrenal insuffi-
c i e n c yr a t e( O R6 . 7 ;9 5 %C I :3 . 5 - 1 2 . 7 ) ;h o w e v e rt h e2 8
day mortality for etomidate was 35% versus 31% for
ketamine (p = 0.36). Subgroup analysis of the 76 septic
patients showed no statistically significant difference in
mortality with etomidate vs. ketamine with an odds
ratio of 1.4 [95%CI 0.5-0.35] [20].
Our study is the first to associate etomidate with
increased ICU mortality in cirrhotic septic shock
patients and alarm to its use in this vulnerable subset of
patients. Our data did not show a statistically significant
association between etomidate use and all cause 28-day
or hospital mortality. This is possibly related to the high
baseline mortality rate in the control group; a finding
which is consistent with reported literature [31,32]. Our
patient population also suffers from high ammonia
levels, well correlated with the presence of portosyste-
mic collateral veins and advanced esophageal varices,
reflecting further on the acuity of our patient population
and possibly making them more vulnerable to vasodila-
tion, worsening hemodynamics and poor prognosis in
septic shock [39]. We observed no significant differences
in adrenal responsiveness with etomidate use, possibly
because of the high prevalence of relative adrenal insuf-
ficiency at baseline. Whether etomidate worsened ICU
mortality via its adrenal suppression effects or through
other mechanisms still warrants further study. However,
etomidate is also well known to cause hypoaldosteron-
ism; to affect levels of interleukin 6 and 10 and may
interfere with circulating lymphocytes levels and pro-
inflammatory mediators necessary in sepsis. The impact
of these factors on patients’ outcomes is still not deter-
mined [40-43].
Hydrocortisone supplementation
Hydrocortisone supplementation in etomidate recipients
to counteract its adrenal suppression effects is also a
Table 2 Outcomes of etomidate vs. control groups
Etomidate Control P-Value
N = 23 N = 39
ICU mortality, No. (%) 21 (91) 25 (64) 0.02
Hospital mortality, No. (%) 23 (100) 37 (95) 0.23
28-day mortality, No. (%) 21 (91) 33 (84) 0.45
Delta norepinephrine (D2-1)
(μ/kg/min), mean ± SD
0.03 ± 0.30 -0.01 ± 0.26 0.61
Delta norepinephrine (D3-1)
(μ/kg/min), mean ± SD
0.07 ± 0.37 -0.06 ± 0.33 0.15
ICU length of stay (days), mean ± SD 12.6 ± 7.8 9.4 ± 5.8 0.06
Ventilation-free days, mean ± SD 2.3 ± 4.6 6.0 ± 7.5 0.02
Vasopressor-free days, mean ± SD 3.2 ± 6 5.5 ± 7.8 0.23
Table 3 Outcomes of etomidate vs. control stratified by hydrocortisone use
Etomidate (n = 23) Control (n = 39)
Hydrocortisone Placebo P-Value Hydrocortisone Placebo P-value
N = 14 N = 9 N = 20 N = 19
ICU mortality, No.% 12 (85.7) 9 (100) 0.50 12 (60) 13 (68.4) 0.74
Hospital mortality, No.% 14 (100) 9 (100) 18 (90) 19 (100) 0.49
28-day mortality, No.% 13 (92.9) 8 (88.9) 1.0 18 (90) 15 (79) 0.41
Delta norepinephrine (d2-1) (μ/kg/min) -0.05 ± 0.23 0.15 ± 0.36 0.05 -0.10 ± 0.24 0.08 ± 0.25 0.02
Delta norepinephrine (d3-1) (μ/kg/min) -0.10 ± 0.26 0.31 ± 0.36 0.01 -0.20 ± 0.33 0.06 ± 0.28 0.02
ICU length of stay (days), mean ± SD 13.7 ± 7.2 10.9 ± 8.5 0.23 9.4 ± 5.9 9.3 ± 5.6 0.93
Ventilation-free days, mean ± SD 3.6 ± 5.6 0.2 ± 0.4 0.04 6.2 ± 6.6 5.8 ± 8.5 0.6
Vasopressor-free days, mean ± SD 4.6 ± 6.9 1.1 ± 3.3 0.05 7.1 ± 8.0 3.8 ± 7.5 0.20
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randomized placebo controlled trial a reduction in mor-
tality among septic shock patients who received low-
dose hydrocortisone [38]. Subgroup analysis of the 68
ACTH test non-responders who had received etomidate
showed higher ICU and hospital mortality rates in those
who had been randomized to placebo vs. corticosteroids
( 7 5 . 7 %v s .5 4 . 8 % ;P=0 . 0 3 ) .B a s e do nt h e s er e s u l t s ,t h e
investigators suggested that hydrocortisone therapy
should be administered to all septic patients who receive
etomidate [26]. However, contrary to the Annane study,
Cuthberston et al. in the CORTICUS showed no
improvement in mortality in patients supplemented with
hydrocortisone [17]. Again, this raises the to question
whether the increased mortality by etomidate is due to
unknown reasons beyond adrenal suppression.
Looking at our cirrhotic septic patients, hydrocorti-
sone supplementation in the etomidate group lead to
more ventilator free days and vasopressor-free days but
this did not translate into significant improvement in
ICU mortality, hospital mortality or 28 day mortality. In
the placebo group, hydrocortisone supplementation also
improved hemodynamics through lowering vasopressor
requirements but this did not translate into statistically
significant improvement in mortality.
We observed 100% mortality in the group that
received etomidate but no hydrocortisone. On the other
hand, the lowest ICU mortality was observed in the
group of patients who did not receive etomidate but
received hydrocortisone (Figure 1). These results suggest
that etomidate may be harmful in cirrhotic septic
patients and that hydrocortisone may be beneficial if no
etomidate is administered. However, these hypotheses
need to be confirmed in future randomized controlled
trials. Subsequent hydrocortisone replacement to
etomidate seems to be associated with improved hemo-
dynamics irrespective of the mechanism; being by adre-
nal replacement or by other anti-inflammatory actions
and vascular hyporeactivity as suggested by other litera-
ture and this warrants further study [44].
The results of our study should be interpreted in light
of its strengths and limitations. Strengths include being
the first study examining this important population, pro-
spective data collection and being nested within a ran-
domized controlled trial. On the other hand, the study
is monocenter and the timing of ACTH test was not
protocolized to etomidate administration due to the
dynamics of the study and the emergent nature of intu-
bations. Although, this might have affected measure-
ments of adrenal function, it mimics real-life situations
a n dw o u l dn o th a v ea f f e c t e dt h em a i ne n d p o i n t so ft h e
study which were the clinical outcomes.
Conclusions
We found that in this group of septic cirrhotic patients
with very high mortality, etomidate increased ICU mor-
tality. Subsequent use of hydrocortisone leads to reduc-
tion in vasopressor requirements but not mortality
reduction. The lowest mortality was observed in patients
who did not receive etomidate but received hydrocorti-
sone. Our findings suggest the need for a large rando-
mized controlled trial examining etomidate with
hydrocortisone supplementation versus hydrocortisone
alone in septic cirrhotic patients.
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